Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy
| Autor: | Laura A. A. Gilliam, Jennifer S. Moylan, Michael B. Reid, Leigh Ann Callahan, Marius P. Sumandea |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
medicine.medical_specialty
Chemotherapy Physiology business.industry medicine.medical_treatment Muscle weakness Inflammation Pharmacology Diaphragm (structural system) Cellular and Molecular Neuroscience Route of administration Endocrinology Physiology (medical) Internal medicine medicine Respiratory muscle Doxorubicin Neurology (clinical) Respiratory system medicine.symptom business medicine.drug |
| Zdroj: | Muscle & Nerve. 43:94-102 |
| ISSN: | 0148-639X |
| DOI: | 10.1002/mus.21809 |
| Popis: | Doxorubicin is a chemotherapeutic agent prescribed for a variety of tumors. While undergoing treatment, patients exhibit frequent symptoms that suggest respiratory muscle weakness. Cancer patients can receive doxorubicin chemotherapy through either intravenous (IV) or intraperitoneal (IP) injections. We hypothesized that respiratory muscle function would be depressed in a murine model of chemotherapy. We tested this hypothesis by treating C57BL/6 mice with a clinical dose of doxorubicin (20 mg/kg) via IV or IP injection. Three days later we measured contractile properties of muscle fiber bundles isolated from the diaphragm. Doxorubicin consistently depressed diaphragm force with both methods of administration (P < 0.01). Doxorubicin IP exaggerated the depression in diaphragm force and stimulated tissue inflammation and muscle fiber injury. These results suggest that clinically relevant doses of doxorubicin cause respiratory muscle weakness and that the loss of function depends, in part, on the route of administration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text